Efficacy and Safety of DHEA for Myotonic Dystrophy
Myotonic Dystrophy
About this trial
This is an interventional treatment trial for Myotonic Dystrophy focused on measuring myotonic dystrophy, hypersomnia, dehydroepiandrosterone
Eligibility Criteria
Inclusion Criteria: Myotonic dystrophy (genetically proven) MDRS score of 3 or 4 Exclusion Criteria: Age <18 years or >70 years Pregnancy or breastfeeding Poor compliance to treatment and follow up Inclusion in any other clinical trial Severe cardiac disease: acute myocardial infarction in the preceding 6 months, unstable heart failure, uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg after 10 minutes of rest in the lying position), severe arteritis, any past history of thrombose or embolic event, any past history of symptomatic arrhythmia) Chronic renal failure Chronic liver disease Long term mechanical ventilation Any ongoing cancer Any underlying endocrine disorders Impaired swallowing Previous treatment with DHEA
Sites / Locations
- CHU
- CHU
- Raymond Poincaré Hospital
- CHU
- CHU
- CHU Pouget
- CHU
- Institut de myologie
- CHU
- CHU